title: Pharmacokinetic evaluation of a sustained-release formulation of trihexyphenidyl in healthy volunteers.
abstract: Twenty-four male subjects were randomized to receive two oral dosage forms of trihexyphenidyl HCl (alpha-cyclohexyl-alpha-phenyl-1-piperidinepropanol HCl). The dosage regimens were (1) a 5-mg immediate release (IR) tablet given twice daily at time zero and 12 h later, and (2) two 5-mg sustained-release (SR) capsule formulations given daily. The number of adverse experiences following the SR formulation were approximately 50% of those for the IR formulation, the peak concentration (Cmax) after the SR formulation was significantly lower (p less than 0.05) than that after the first dose of the IR formulation, and the time to reach Cmax (tmax) was significantly longer after the SR formulation (p less than 0.05). The SR formulation maintained serum concentrations above 50, 60, and 70% of Cmax values for average time periods of 11.7, 9.4, and 5.9 h, respectively, compared with values of 1.8, 1.2, and 0.9 h after the IR formulation; the differences were all significant (p less than 0.05). The mean elimination half-life (t1/2) was similar (p greater than 0.05) after the SR (10.1 h) and IR (8.7 h) formulations. The statistical power of the study was 98.1% to detect a 20% difference in the area under the curve from time zero to time infinity (AUC0----infinity) between formulations. Although the AUC0----infinity after the SR formulation was statistically smaller (p less than 0.05) than after the IR tablet, the difference was less than 20%. Therefore, the SR formulation was bioequivalent to the IR tablet formulation of trihexyphenidyl.
authors.affiliation: Medical Research Division, American Cyanamid Company, Pearl River, NY 10965.
authors.forename: W K
authors.initials: WK
authors.lastname: Cheung
authors.forename: S S
authors.initials: SS
authors.lastname: Stravinski
authors.forename: S I
authors.initials: SI
authors.lastname: Engel
authors.forename: L L
authors.initials: LL
authors.lastname: Sia
authors.forename: A
authors.initials: A
authors.lastname: Yacobi
authors.forename: B M
authors.initials: BM
authors.lastname: Silber
mesh_terms: D000328:Adult; D003692:Delayed-Action Preparations; D006801:Humans; D008297:Male; D014282:Trihexyphenidyl / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*
chemical_list: D003692:Delayed-Action Preparations; D014282:Trihexyphenidyl